mir-145
| MicroRNA 145 | |||||
|---|---|---|---|---|---|
| Identifiers | |||||
| Symbols | MIR145 ; MIRN145; miR-145; miRNA145 | ||||
| External IDs | OMIM: 611795 GeneCards: MIR145 Gene | ||||
| |||||
| Orthologs | |||||
| Species | Human | Mouse | |||
| Entrez | 406937 | n/a | |||
| Ensembl | ENSG00000269936 | n/a | |||
| UniProt | n/a | n/a | |||
| RefSeq (mRNA) | NR_029686 | n/a | |||
| RefSeq (protein) | n/a | n/a | |||
| Location (UCSC) |
Chr 5: 149.43 – 149.43 Mb | n/a | |||
| PubMed search | n/a | ||||
| mir-145 | |
|---|---|
 | |
| Conserved secondary structure of mir-145 | |
| Identifiers | |
| Symbol | mir-145 |
| Rfam | RF00675 |
| miRBase family | MIPF0000079 |
| Other data | |
| RNA type | microRNA |
| Domain(s) | Eukaryota; |
In molecular biology, mir-145 microRNA is a short RNA molecule that in humans is encoded by the MIR145 gene. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.[1]
Targets
MicroRNAs are involved in down-regulation of a variety of target genes. Götte et al. have shown that experimental over-expression of mir-145 down-regulates the junctional cell adhesion molecule JAM-A as well as the actin bundling protein fascin.[2] Larsson et al.[3] showed that miR-145 targets the 3' UTR of the FLI1 gene, a finding that was later supported by Zhang et al.[4]
Role in cancer
miR-145 is hypothesised to be a tumor suppressor.[5] miR-145 has been shown to be down-regulated in breast cancer.[2] miR-145 is also involved in colon cancer [4][6] and acute myeloid leukemia.[7]
References
- ↑ "Entrez Gene: MicroRNA 145". Retrieved 2015-01-26.
- 1 2 Götte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, Ebnet K, Kiesel L, Yip GW (Dec 2010). "miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness". Oncogene 29 (50): 6569–80. doi:10.1038/onc.2010.386. PMID 20818426.
- ↑ Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat C, Schermer B, Benzing T, Harvey SJ, Kreuger J, Lindahl P (2009). "Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1". Genome Medicine 1 (11): 108. doi:10.1186/gm108. PMC 2808743. PMID 19917099.
- 1 2 Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X, Hoffman AR, Hu JF, Ge S (Jan 2011). "Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene". Cancer 117 (1): 86–95. doi:10.1002/cncr.25522. PMC 2995010. PMID 20737575.
- ↑ Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY (Mar 2009). "p53 represses c-Myc through induction of the tumor suppressor miR-145". Proceedings of the National Academy of Sciences of the United States of America 106 (9): 3207–12. doi:10.1073/pnas.0808042106. PMC 2651330. PMID 19202062.
- ↑ Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R (2007). "Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer". Oncology 72 (5-6): 397–402. doi:10.1159/000113489. PMID 18196926.
- ↑ Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam WL, Marra M, Karsan A (Jan 2011). "Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations". Blood 117 (2): 595–607. doi:10.1182/blood-2010-03-277012. PMID 20962326.
Further reading
- Zhang J, Guo H, Qian G, Ge S, Ji H, Hu X, Chen W (2010). "MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network". Molecular Cancer 9: 211. doi:10.1186/1476-4598-9-211. PMC 2924312. PMID 20687965.
- Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Dahiya R (Jul 2010). "The functional significance of microRNA-145 in prostate cancer". British Journal of Cancer 103 (2): 256–64. doi:10.1038/sj.bjc.6605742. PMC 2906737. PMID 20588276.
- Sachdeva M, Mo YY (2010). "miR-145-mediated suppression of cell growth, invasion and metastasis". American Journal of Translational Research 2 (2): 170–80. PMC 2855636. PMID 20407606.
- Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H (Dec 2010). "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma". International Journal of Cancer. Journal International Du Cancer 127 (12): 2804–14. doi:10.1002/ijc.25284. PMID 21351259.
- Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M (Mar 2010). "miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer". British Journal of Cancer 102 (5): 883–91. doi:10.1038/sj.bjc.6605570. PMC 2833258. PMID 20160723.
- Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH (2010). Kudla G, ed. "MicroRNA-145 targets YES and STAT1 in colon cancer cells". PLOS ONE 5 (1): e8836. doi:10.1371/journal.pone.0008836. PMC 2809101. PMID 20098684.
- Sachdeva M, Mo YY (Jan 2010). "MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1". Cancer Research 70 (1): 378–87. doi:10.1158/0008-5472.CAN-09-2021. PMC 2805032. PMID 19996288.
- Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat C, Schermer B, Benzing T, Harvey SJ, Kreuger J, Lindahl P (2009). "Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1". Genome Medicine 1 (11): 108. doi:10.1186/gm108. PMC 2808743. PMID 19917099.
- Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, Ulhøi B, Borre M, Kjems J, Dyrskjøt L, Orntoft TF (Feb 2010). "miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors". Oncogene 29 (7): 1073–84. doi:10.1038/onc.2009.395. PMID 19915607.
- Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A (Jan 2010). "Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype". Nature Medicine 16 (1): 49–58. doi:10.1038/nm.2054. PMID 19898489.
- Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M (2009). "Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer". BMC Cancer 9: 374. doi:10.1186/1471-2407-9-374. PMC 2770572. PMID 19843336.
- Zhang C (Nov 2009). "MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease". Cell Cycle 8 (21): 3469–73. doi:10.4161/cc.8.21.9837. PMID 19829088.
- Zeng L, Carter AD, Childs SJ (Oct 2009). "miR-145 directs intestinal maturation in zebrafish". Proceedings of the National Academy of Sciences of the United States of America 106 (42): 17793–8. doi:10.1073/pnas.0903693106. PMC 2764920. PMID 19805048.
- Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA (Feb 2010). "miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells". Cell Death and Differentiation 17 (2): 246–54. doi:10.1038/cdd.2009.117. PMID 19730444.
- Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, Richardson JA, Bassel-Duby R, Olson EN (Sep 2009). "MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury". Genes & Development 23 (18): 2166–78. doi:10.1101/gad.1842409. PMC 2751981. PMID 19720868.
- Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D (Aug 2009). "miR-145 and miR-143 regulate smooth muscle cell fate and plasticity". Nature 460 (7256): 705–10. doi:10.1038/nature08195. PMC 2769203. PMID 19578358.
- Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C (Jul 2009). "MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation". Circulation Research 105 (2): 158–66. doi:10.1161/CIRCRESAHA.109.197517. PMC 2728297. PMID 19542014.
- Cho WC, Chow AS, Au JS (Aug 2009). "Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation". European Journal of Cancer 45 (12): 2197–206. doi:10.1016/j.ejca.2009.04.039. PMID 19493678.
- Chivukula RR, Mendell JT (May 2009). "Abate and switch: miR-145 in stem cell differentiation". Cell 137 (4): 606–8. doi:10.1016/j.cell.2009.04.059. PMID 19450510.
- Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (May 2009). "MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells". Cell 137 (4): 647–58. doi:10.1016/j.cell.2009.02.038. PMID 19409607.
- La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, Baserga R (Aug 2009). "Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway". Journal of Cellular Physiology 220 (2): 485–91. doi:10.1002/jcp.21796. PMID 19391107.
- Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H, Zhao RC (May 2009). "miR-145 inhibits breast cancer cell growth through RTKN". International Journal of Oncology 34 (5): 1461–6. PMID 19360360.
- Zheng L, Pu J, Qi T, Qi M, Li D, Xiang X, Huang K, Tong Q (Feb 2013). "miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells". Molecular Cancer Research 11 (2): 182–93. doi:10.1158/1541-7786.MCR-12-0534. PMID 23233482.
External links
| ||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, January 24, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.